Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells |
| |
Authors: | James J Mulé Susan L Schwarz Anita B Roberts Michael B Sporn Steven A Rosenberg |
| |
Institution: | (1) Surgery Branch, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, 20892 Bethesda, MD, USA;(2) Laboratory of Chemoprevention, Division of Cancer Etiology, National Cancer Institute, National Institutes of Health, 20892 Bethesda, MD, USA |
| |
Abstract: | Summary The effect(s) of purified transforming growth factor-beta (TGF-beta) and platelet-derived growth factor (PDGF) on the induction and function of lymphokine-activated killer (LAK) cells and cytotoxic T lymphocytes (CTL) was examined. The addition of TGF-beta, but not PDGF, to cultures containing fresh C57BL/6 mouse splenocytes or human peripheral blood lymphocytes plus recombinant interleukin-2 markedly inhibited the development of mouse and human LAK cell activity (measured after 3 days for cytotoxicity against cultured or fresh tumor targets in 4-h 51Cr release assays). The addition of TGF-beta, but not PDGF, to a one-way, C57BL/6 anti-DBA/2, mixed lymphocyte reaction effectively blocked the generation of allospecific CTL as well. However, TGF-beta did not inhibit the effector function of LAK cells or of allospecific CTL when added directly to the short-term cytolytic assay. A second form of homodimeric TGF-beta, type 2, was also found to be suppressive on the development of murine LAK cells and allospecific CTL. Collectively, these data demonstrate that the peptide TGF-beta is a potent inhibitor of LAK cell and CTL generation in vitro. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|